Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans

2013 Saha, 2005, A systematic review of the prevalence of schizophrenia, PLoS medicine, 2, e141, 10.1371/journal.pmed.0020141 Lehman, 2004, The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003, Schizophrenia bulletin, 30, 193, 10.1093/oxfordjournals.schbul.a007071 Kane, 2007, Treatment adherence and long-term outcomes, CNS Spectrums, 12, 21, 10.1017/S1092852900026304 Dixon, 2009, Guideline Watch (September 2009): Practice guidelines for the treatment of patients with schizophrenia, American Psychiatric Association Practice Guidelines Thieda, 2003, An Economic review of compliance with medication therapy in the treatment of schizophrenia, Psychiatric services, 54, 508, 10.1176/appi.ps.54.4.508 Novick, 2010, Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia, Psychiatry research, 176, 109, 10.1016/j.psychres.2009.05.004 Cooper, 2007, Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia, The journal of clinical psychiatry, 68, 818, 10.4088/JCP.v68n0601 Lacro, 2002, Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature, The journal of clinical psychiatry, 63, 892, 10.4088/JCP.v63n1007 Marcus, 2015, Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge, Journal of managed care & specialty pharmacy, 21, 754, 10.18553/jmcp.2015.21.9.754 Alphs, 2015, Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study, The journal of clinical psychiatry, 76, 554, 10.4088/JCP.14m09584 Hough, 2010, Paliperidone palmitate maintenance treatment in delaying the time to relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study, Schizophrenia research, 116, 107, 10.1016/j.schres.2009.10.026 Joshi, 2015, Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder, Journal of medical economics, 18, 629, 10.3111/13696998.2015.1033424 Schreiner, 2015, Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia, Schizophrenia research, 169, 393, 10.1016/j.schres.2015.08.015 Fu, 2015, Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder, The Journal of clinical psychiatry, 76, 253, 10.4088/JCP.14m09416 Osborne, 2012, Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study, Health and quality of life outcomes, 10, 35, 10.1186/1477-7525-10-35 Viala, 2012, Treatment adherence with early prescription of long-acting injectable antipsychotics in recent-onset schizophrenia, Schizophrenia research and treatment, 2012, 10.1155/2012/368687 Nasrallah, 2004, Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone, The journal of clinical psychiatry, 65, 531, 10.4088/JCP.v65n0412 Potkin, 2009, Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs, haloperidol. International journal of neuropsychopharmacology, 12, 1233, 10.1017/S1461145709000352 Alonso, 2009, Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the Schizophrenia Health Outcomes (SOHO) study, Value in health, 12, 536, 10.1111/j.1524-4733.2008.00495.x Berwaerts, 2015, Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial, JAMA psychiatry, 72, 830, 10.1001/jamapsychiatry.2015.0241 Joshi, 2017, Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting, Current medical research and opinion, 33, 1763, 10.1080/03007995.2017.1359516 Quan, 2011, Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries, American journal of epidemiology, 173, 676, 10.1093/aje/kwq433 Charlson, 1987, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, Journal of chronic diseases, 40, 373, 10.1016/0021-9681(87)90171-8 Andrade, 2006, Methods for evaluation of medication adherence and persistence using automated databases, Pharmacoepidemiology and drug safety, 15, 565, 10.1002/pds.1230 Elixhauser A, Steiner C, Kruzikas D. Health care Cost and Utilization Project (HCUP) Comorbidity Software. 2015. Rockville, Md: Agency for Health care Research and Quality. Available from: https://www.hcup-us.ahrq.gov/toolssoftware/comorbidity/comorbidity.jsp#download.2 Dilla, 2013, Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia, Patient preference and adherence, 7, 275, 10.2147/PPA.S41609 Einarson, 2017, Cost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in Spain, Journal of medical economics, 20, 1039, 10.1080/13696998.2017.1351370 Einarson, 2017, Cost effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands, Journal of medical economics, 1 Savitz, 2017, Efficacy and safety of paliperidone palmitate three monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study, Neuropsychiatric disease and treatment, 13, 2193, 10.2147/NDT.S134287 Savitz, 2016, Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study, The international journal of neuropsychopharmacology, 19, 10.1093/ijnp/pyw018 Farley, 2012, Antipsychotic adherence and its correlation to health outcomes for chronic comorbid conditions, The primary care companion to CNS disorders, 14: Hansen, 2012, Adherence to antipsychotics and cardiometabolic medication: association with health care utilization and costs, Psychiatric services, 63, 920, 10.1176/appi.ps.201100328 Novick, 2009, Recovery in the outpatient setting: 36- month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study, Schizophrenia research, 108, 223, 10.1016/j.schres.2008.11.007 US Dept Veterans Affairs. Depart-ment of Veterans Affairs Statistics at a Glance. 2016. Available at: https://www.va.gov/vetdata/docs/Quickfacts/Homepage_slideshow_06_04_16.pdf. Accessed January 22, 2018 National Center for Veterans Analysis and Statistics. Profile of Veterans: 2015 Data from the American Community Survey. 2017. Brasso, 2017, Role of 3-monthly long acting injectable paliperidone in the maintenance of schizophrenia, Neuropsychiatric disease and treatment, 13, 2767, 10.2147/NDT.S150568 Emsley, 2018, Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review, Neuropsychiatric disease and treatment, 14, 205, 10.2147/NDT.S139633